1. Home
  2. CGO vs ELTX Comparison

CGO vs ELTX Comparison

Compare CGO & ELTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CGO
  • ELTX
  • Stock Information
  • Founded
  • CGO 2004
  • ELTX 2011
  • Country
  • CGO United States
  • ELTX United States
  • Employees
  • CGO N/A
  • ELTX N/A
  • Industry
  • CGO Investment Managers
  • ELTX Biotechnology: Pharmaceutical Preparations
  • Sector
  • CGO Finance
  • ELTX Health Care
  • Exchange
  • CGO Nasdaq
  • ELTX Nasdaq
  • Market Cap
  • CGO 111.0M
  • ELTX 121.7M
  • IPO Year
  • CGO N/A
  • ELTX N/A
  • Fundamental
  • Price
  • CGO $11.63
  • ELTX $7.72
  • Analyst Decision
  • CGO
  • ELTX Strong Buy
  • Analyst Count
  • CGO 0
  • ELTX 2
  • Target Price
  • CGO N/A
  • ELTX $9.50
  • AVG Volume (30 Days)
  • CGO 34.7K
  • ELTX 57.8K
  • Earning Date
  • CGO 01-01-0001
  • ELTX 08-12-2025
  • Dividend Yield
  • CGO 9.25%
  • ELTX N/A
  • EPS Growth
  • CGO N/A
  • ELTX N/A
  • EPS
  • CGO N/A
  • ELTX N/A
  • Revenue
  • CGO N/A
  • ELTX N/A
  • Revenue This Year
  • CGO N/A
  • ELTX N/A
  • Revenue Next Year
  • CGO N/A
  • ELTX N/A
  • P/E Ratio
  • CGO N/A
  • ELTX N/A
  • Revenue Growth
  • CGO N/A
  • ELTX N/A
  • 52 Week Low
  • CGO $7.90
  • ELTX $3.34
  • 52 Week High
  • CGO $10.93
  • ELTX $9.99
  • Technical
  • Relative Strength Index (RSI)
  • CGO 65.54
  • ELTX 55.57
  • Support Level
  • CGO $11.30
  • ELTX $7.70
  • Resistance Level
  • CGO $11.45
  • ELTX $8.19
  • Average True Range (ATR)
  • CGO 0.12
  • ELTX 0.36
  • MACD
  • CGO -0.00
  • ELTX -0.09
  • Stochastic Oscillator
  • CGO 92.68
  • ELTX 19.05

About CGO Calamos Global Total Return Fund

Calamos Global Total Return Fund is a closed-end management investment company. The fund's investment objective is to provide total return through a combination of capital appreciation and current income. The fund invests in equities, convertible securities, and high-yield corporate bonds.

About ELTX Elicio Therapeutics Inc.

Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking. Elicio is engineering lymph node-targeted AMPlifiers, immunomodulators, adjuvants, and vaccines for an array of aggressive cancers. It has developed its cancer vaccine product candidates to target biologically validated tumor mutation drivers using known neoantigens.

Share on Social Networks: